Why We're Not Close to AI Drugs Yet | Isomorphic Labs

2026-02-18 · Source: Weights & Biases · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Emerging Technologies & Innovation, AI in Drug Discovery · Depth: Intermediate, quick

Summary

Drug design is not a singular machine learning problem but a complex array of challenges requiring specific system representations. While AlphaFold 2 significantly advanced the field by fundamentally solving protein structure prediction, it did not resolve drug design entirely. Instead, its success has highlighted approximately ten additional "AlphaFold-like" challenges that need to be addressed. These challenges involve intricate scientific questions related to designing drugs with desired properties for effective administration, with structural prediction serving as a foundational precursor to these more complex downstream problems.

Key takeaway

For AI Researchers focused on drug discovery, recognize that your efforts should target specific, discrete challenges within the broader drug design pipeline. AlphaFold 2's success in protein structure prediction demonstrates the value of solving foundational problems, but your next steps should involve identifying and tackling the remaining "AlphaFold-like" challenges to achieve comprehensive drug design solutions.

Key insights

Drug design comprises multiple distinct ML problems, not a single one, despite AlphaFold 2's protein structure prediction success.

Principles

• Complex problems decompose into sub-problems.
• Foundational solutions enable further breakthroughs.

In practice

• Identify specific sub-problems in complex tasks.
• Prioritize foundational scientific questions.

Topics

• Drug Design
• Machine Learning
• Protein Structure Prediction
• AlphaFold 2
• Computational Drug Discovery

Best for: AI Scientist, AI Researcher, Research Scientist

Related on AIssential

• 😺 🎙️ Watch: How Isomorphic Labs works to drug "undruggable" diseases — AI, particularly AlphaFold-derived technology, is dramatically accelerating drug discovery and tackling previously "undruggable" targets.
• AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials — AlphaFold, known for protein understanding, is now being tested for drug design capabilities.
• How a Google DeepMind Spinoff Hunts Hidden Drug Targets — IsoDDE enables discovery of novel, cryptic protein binding pockets, expanding druggable targets beyond AlphaFold's capabilities.
• Is AI Drug Discovery Becoming a Data Infrastructure Race? — AI drug discovery's primary bottleneck is the availability of diverse, relevant biological training data, not model architecture or compute.
• AlphaFold: Grand Challenge to Nobel Prize with John Jumper — AlphaFold's success demonstrates AI's profound utility in accelerating scientific discovery, even without full interpretability.
• AF2BIND: predicting small-molecule binding sites using the pair representation of AlphaFold2 — AlphaFold2's internal representations can be repurposed to accurately predict de novo small-molecule binding sites.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Weights & Biases.